Getting Uncomfortable with Esketamine
The Carlat Psychiatry Report, Volume 18, Number 1, January 2020
Topics: Antidepressant Augmentation | Antidepressants | Brain Devices | Depression | Depressive Disorder | ECT | Esketamine | Ketamine | Neurotoxicity | Novel Medications | rTMS | Suicidality | TMS | Transcranial Magnetic Stimulation | Treatment-Resistant Depression
Nolan Williams, MD
Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA.
Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.